Highest-materiality recent filing
Enliven reports Q4/FY2025 results; initial Phase 1b data for ELVN-001 shows MMR rates 47-69%
Net loss of $29.7M for Q4 2025 vs $23.2M for Q4 2024; full year net loss $103.7M vs $89.0M.
Enliven Therapeutics appoints Scott Garland to board; Phillips resigns as ELVN prepares for Phase 3
Scott Garland appointed as Class I director and Chair of Nominating and Corporate Governance Committee effective Jan 7, 2026.
Enliven Therapeutics names Richard Fair CEO; co-founder Sam Kintz becomes Head of Pipeline
Richard Fair appointed President, CEO and board member, effective December 11, 2025.
Enliven Therapeutics Q3 2025 net loss $20.1M; completed Phase 1b enrollment for ELVN-001 in CML
Completed enrollment of randomized Phase 1b cohorts of ENABLE trial of ELVN-001 in CML; on track for Phase 3 pivotal trial in 2026.
Enliven Q3 net loss $20.1M; cash $477.6M; Phase 1b enrollment completed for ELVN-001
Net loss $20.1M in Q3 2025 vs $23.2M in Q3 2024; R&D expenses $18.2M vs $21.3M.
Enliven reports Q2 net loss $25.3M; positive ELVN-001 Phase 1 data with 47% MMR rate
Phase 1 trial of ELVN-001 in CML: 47% cumulative MMR rate; 32% achieved MMR by 24 weeks, favorable safety.
Enliven Therapeutics prices $200M public offering of common stock and pre-funded warrants
Offering of 8.39M shares at $19.66/share and 1.78M pre-funded warrants at $19.659/warrant; gross proceeds ~$200M.
Enliven reports 47% cumulative MMR by 24 weeks for ELVN-001 in Phase 1 CML trial; well-tolerated
47% of evaluable patients (25/53) achieved MMR by 24 weeks; 32% (13/41) achieved MMR, comparing favorably to asciminib's 24% in Phase 1.
Enliven Q1 net loss $28.5M; ELVN-001 44% MMR rate at 24 weeks, cash $290M
Net loss of $28.5M for Q1 2025 vs $22.7M Q1 2024; R&D expenses $24.9M.
Enliven Therapeutics Q4 2024 net loss $23.2M; cash $313.4M; pipeline milestones set for 2025
Net loss $23.2M in Q4 2024 ($19.4M in Q4 2023); full year 2024 net loss $89.0M ($71.6M in FY2023).
Enliven Q3 net loss $23.2M; ELVN-001 Phase 1 MMR rate 44% by 24 weeks
Cash $291.8M as of Sept 30, 2024; runway into late 2026.
Cash, cash equivalents and marketable securities of $312.4M as of June 30, 2024, expected to fund operations into late 2026.
Enliven Therapeutics Q1 net loss $22.7M; ELVN-001 Phase 1 shows 44% MMR at 12 weeks
Net loss of $22.7M for Q1 2024 vs $14.7M in Q1 2023; cash, equivalents & marketable securities $320.5M.
Enliven Therapeutics reports positive Phase 1 data for ELVN-001 in CML; 44% MMR rate at 12 weeks
Cumulative MMR rate of 44% (7/16) by 12 weeks in response-evaluable CML patients; 44% (4/9) in post-asciminib patients.
Enliven Therapeutics raises $90M in PIPE, extends cash runway into late 2026
Gross proceeds ~$90M from sale of 5.36M shares at $14.00 and pre-funded warrants at $13.999.
On April 8, 2024, the Board of Directors (the “Board”) of Enliven Therapeutics, Inc. (the “Company”) appointed Lori Kunkel, MD to serve as a Class III director, with a term expiring at the Company’s 2026 annual meeting of stockholders.
Max materiality 0.85 · Median 0.60 · Most common event earnings